Megha Manchanda &Amp;Amp; Sohini Das

Stories by Megha Manchanda &Amp;Amp; Sohini Das

50 Mn To 100 Mn Indians Suffer From Long Covid

50 Mn To 100 Mn Indians Suffer From Long Covid

Rediff.com   3 days ago

Even by conservative assumptions that 5 to 10 per cent of infected individuals develop long Covid, India today may be home to 50 to 100 million infected individuals -- many silently coping with breathlessness, fatigue, palpitations, brain fog, or unexplained clotting tendencies.

Seniors to Drive 25% of India's Pharma

Seniors to Drive 25% of India's Pharma

Rediff.com   21 Nov 2025

'Once the 60-plus population hits 20 to 30 per cent of the country, the demand for elderly-care treatments will surge -- cardiac, metabolic, neurological, and musculoskeletal medicines are going to dominate the market for the next several decades.'

Pune Firm Unveils Diabetes-Control Implant

Pune Firm Unveils Diabetes-Control Implant

Rediff.com   19 Nov 2025

This innovation works by stimulating our natural organs so that it can produce and maintain the insulin balance.

VinFast Outsells Tesla in Festival Season But BYD Is King

VinFast Outsells Tesla in Festival Season But BYD Is King

Rediff.com   10 Nov 2025

Vinfast sold 137 cars versus Tesla's 109 during the festive months of September and October, as BYD maintained a strong lead with over 1,100 cars sold, according to Fada data.

USFDA's new draft biosimilar rules to benefit Indian biotech cos

USFDA's new draft biosimilar rules to benefit Indian biotech cos

Rediff.com   9 Nov 2025

The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.

Bajaj Auto posts highest ever quarterly revenue and PAT

Bajaj Auto posts highest ever quarterly revenue and PAT

Rediff.com   8 Nov 2025

Pune-based two-wheeler major Bajaj Auto posted its highest ever quarterly revenue and profit after tax (PAT) in Q2FY26. Even as consolidated revenues were up 18.8 per cent year-on-year (Y-o-Y) to Rs 15,734.7 crore, PAT zoomed 53.2 per cent to Rs 2,122 crore.

Where The Deadly Cough Syrup Was Made

Where The Deadly Cough Syrup Was Made

Rediff.com   18 Oct 2025

Sandwiched between a Hero MotoCorp showroom and a shop that hires out cooking utensils is a small, dingy building that's been locked up. The non-descript two-room building is a manufacturing unit of Sresan Pharmaceuticals, the pharma company made its Coldriff cough syrup that has allegedly killed 25 children in Madhya Pradesh.

Electric PV sales more than double in September; Tata Motors leads

Electric PV sales more than double in September; Tata Motors leads

Rediff.com   9 Oct 2025

Electric passenger vehicle (PV) retail sales jumped more than twofold in September with Tata Motors (TaMo) leading the pack having over 6,000 registrations and a 40 per cent market share.

Mercedes clocks record Navratri sale of 2,500 cars

Mercedes clocks record Navratri sale of 2,500 cars

Rediff.com   8 Oct 2025

'We expect this festival buying spirit to continue in October as well, with upcoming festivities including Dhanteras and Diwali, which traditionally witness spirited buying from customers.'

Indian Cars Race Abroad as Home Sales Stall

Indian Cars Race Abroad as Home Sales Stall

Rediff.com   3 Oct 2025

Between April and August this financial year, passenger car exports rose 8.5 per cent year-on-year (Y-o-Y), while domestic sales fell by 8.5 per cent.

How India Buys A Car Today Has Changed

How India Buys A Car Today Has Changed

Rediff.com   3 Oct 2025

More Indians start car shopping online, pushing automakers and dealers to respond quickly, train staff, and use AI to turn clicks into showroom visits.

When Romance Meets The Rulebook: How Cos Deal With Workplace Relationships

When Romance Meets The Rulebook: How Cos Deal With Workplace Relationships

Rediff.com   24 Sep 2025

Romance may be personal, but when it enters the workplace, particularly in reporting hierarchies, it becomes a matter of governance.

Luxury Cars, Bikes Rev Up For Festival Season

Luxury Cars, Bikes Rev Up For Festival Season

Rediff.com   23 Sep 2025

Luxury carmakers are shifting into high gear with a mix of product launches, personalised experiences and lifestyle-led engagement.

Patients to benefit from GST cut, but pharma firms may face margin pressure

Patients to benefit from GST cut, but pharma firms may face margin pressure

Rediff.com   12 Sep 2025

The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.

Helped by GST move, PV sales growth may rebound to 7% by FY27: Maruti

Helped by GST move, PV sales growth may rebound to 7% by FY27: Maruti

Rediff.com   12 Sep 2025

The country's largest carmaker Maruti Suzuki India expects auto sales to bounce back to the glory days of 7 per cent growth by FY 27, helped by the proposed GST rate cut which is expected to bring down car prices by 3.5 to 8.5 per cent.

Rare Earth Magnet Crunch Persists For Automakers

Rare Earth Magnet Crunch Persists For Automakers

Rediff.com   11 Sep 2025

'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'

How India's pharma cos plan to tackle steep US tariffs

How India's pharma cos plan to tackle steep US tariffs

Rediff.com   10 Sep 2025

As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com   12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Rediff.com   31 Jul 2025

India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.

P&G's New Boss Is Big Into Bollywood Movies

P&G's New Boss Is Big Into Bollywood Movies

Rediff.com   30 Jul 2025

Shailesh Jejurikar has 'always made an effort to stay close to his roots.'